- Home
- NRIX vs ADSE Comparison
NRIX vs ADSE Comparison
Compare NRIX & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- ADSE
- Stock Information
- Founded
- NRIX 2009
- ADSE 1980
- Country
- NRIX United States
- ADSE Ireland
- Employees
- NRIX N/A
- ADSE N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- ADSE Industrial Specialties
- Sector
- NRIX Health Care
- ADSE Consumer Discretionary
- Exchange
- NRIX Nasdaq
- ADSE Nasdaq
- Market Cap
- NRIX 766.0M
- ADSE 644.4M
- IPO Year
- NRIX 2020
- ADSE N/A
- Fundamental
- Price
- NRIX $10.56
- ADSE $11.78
- Analyst Decision
- NRIX Strong Buy
- ADSE
- Analyst Count
- NRIX 15
- ADSE 0
- Target Price
- NRIX $29.13
- ADSE N/A
- AVG Volume (30 Days)
- NRIX 678.5K
- ADSE 76.0K
- Earning Date
- NRIX 10-10-2025
- ADSE 09-11-2025
- Dividend Yield
- NRIX N/A
- ADSE N/A
- EPS Growth
- NRIX N/A
- ADSE N/A
- EPS
- NRIX N/A
- ADSE N/A
- Revenue
- NRIX $88,381,000.00
- ADSE $113,896,884.00
- Revenue This Year
- NRIX $71.51
- ADSE $219.58
- Revenue Next Year
- NRIX N/A
- ADSE N/A
- P/E Ratio
- NRIX N/A
- ADSE N/A
- Revenue Growth
- NRIX 41.86
- ADSE 2.45
- 52 Week Low
- NRIX $8.18
- ADSE $9.00
- 52 Week High
- NRIX $29.56
- ADSE $16.35
- Technical
- Relative Strength Index (RSI)
- NRIX 43.38
- ADSE 48.76
- Support Level
- NRIX $9.44
- ADSE $10.56
- Resistance Level
- NRIX $10.98
- ADSE $11.71
- Average True Range (ATR)
- NRIX 0.57
- ADSE 0.85
- MACD
- NRIX -0.08
- ADSE -0.00
- Stochastic Oscillator
- NRIX 38.75
- ADSE 37.75
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.